155 related articles for article (PubMed ID: 9463174)
41. NTP Toxicology and Carcinogenesis Studies of Nickel Subsulfide (CAS No. 12035-72-2) in F344 Rats and B6C3F1 Mice (Inhalation Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Jul; 453():1-365. PubMed ID: 12594522
[TBL] [Abstract][Full Text] [Related]
42. New protocol for immune tolerance induction in acquired hemophilia.
Nemes L; Pitlik E
Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
[TBL] [Abstract][Full Text] [Related]
43. [Effects on the coagulation-fibrinolysis system of a single oral dose of mesoglycan at the beginning and at the end of a prolonged treatment in man].
Blardi P; Messa G; Puccetti L; La Placa G; Ghezzi A
Recenti Prog Med; 1995; 86(7-8):282-9. PubMed ID: 7569284
[TBL] [Abstract][Full Text] [Related]
44. Spinal cord stimulation in hemodialysis patients with critical lower-limb ischemia.
Brümmer U; Condini V; Cappelli P; Di Liberato L; Scesi M; Bonomini M; Costantini A
Am J Kidney Dis; 2006 May; 47(5):842-7. PubMed ID: 16632023
[TBL] [Abstract][Full Text] [Related]
45. [Controlled multicenter study on the therapeutic effectiveness of mesoglycan in patients with cerebrovascular disease].
Abate G; Berenga A; Caione F; Capodaglio M; Cuzzupoli M; Guido A; Forestiero G; Guizzardi G; Mancini G; Viscanti G
Minerva Med; 1991 Mar; 82(3):101-5. PubMed ID: 1826046
[TBL] [Abstract][Full Text] [Related]
46. [The role of iloprost in the treatment of critical ischemia of the limbs].
Poggesi L; Comeglio M
Ann Ital Med Int; 1993 Oct; 8 Suppl():71S-77S. PubMed ID: 7509614
[TBL] [Abstract][Full Text] [Related]
47. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
48. Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS).
Tsuchida H; Shigematsu H; Ishimaru S; Iwai T; Akaba N; Umezu S
Int Angiol; 2006 Sep; 25(3):287-92. PubMed ID: 16878078
[TBL] [Abstract][Full Text] [Related]
49. [Heparan sulfate in the therapy of postphlebitic syndrome. Evaluation of the efficacy and tolerability as compared to mesoglycan].
Giorgetti PL; Marenghi MC; Bianciardi P
Minerva Cardioangiol; 1997 Jun; 45(6):279-84. PubMed ID: 9432569
[TBL] [Abstract][Full Text] [Related]
50. Treatment of intermittent claudication with defibrotide or mesoglycan. A double blind study.
Laurora G; Ambrosoli L; Cesarone MR; De Sanctis MT; Incandela L; Marelli C; Belcaro G
Panminerva Med; 1994 Jun; 36(2):83-6. PubMed ID: 7831064
[TBL] [Abstract][Full Text] [Related]
51. [Essential arterial hypertension and Leriche-Fontaine stage II obliterating vascular disease of the lower limbs. A new pharmacological approach with ketanserin].
Mollo P
Clin Ter; 1991 Apr; 137(2):113-5. PubMed ID: 1828404
[TBL] [Abstract][Full Text] [Related]
52. [Therapeutic action of oral mesoglycan in the pharmacologic treatment of the varicose syndrome and its complications].
Petruzzellis V; Velon A
Minerva Med; 1985 Mar; 76(12):543-8. PubMed ID: 3157887
[TBL] [Abstract][Full Text] [Related]
53. [Use of a minor fibrinolytic drug (mesoglycan) in phlebitis].
Scondotto G; De Fabritiis A; Guastarobba A; Amato AC; Filippini M
Minerva Med; 1984 Jul; 75(28-29):1733-8. PubMed ID: 6236381
[TBL] [Abstract][Full Text] [Related]
54. [Use of nitrendipine in treating patients with obliterative atherosclerosis of arteries in the lower extremities].
Grodzińska L; Kostka-Trabka E; Basista M; Bieroń K; Sławiński M; Telesz E
Pol Tyg Lek; 1991 Aug 5-19; 46(32-34):598-600. PubMed ID: 1669121
[TBL] [Abstract][Full Text] [Related]
55. [Effects of 2 single oral doses of mesoglycan on the coagulation-fibrinolysis system in man. A pharmacodynamic study].
Messa G; Blardi P; La Placa G; Puccetti L; Ghezzi A
Recenti Prog Med; 1995; 86(7-8):272-81. PubMed ID: 7569283
[TBL] [Abstract][Full Text] [Related]
56. [Intermittent claudication: topical treatment with isosorbide dinitrate ointment. Preliminary results].
Biagini A; Carpeggiani C; Testa R; Mazzei MG; Michelassi C; L'Abbate A
G Ital Cardiol; 1981; 11(7):983-9. PubMed ID: 7308655
[TBL] [Abstract][Full Text] [Related]
57. Mesoglycan improves vascular reactivity and insulin sensitivity in patients with metabolic syndrome.
Valvano A; Bosso G; Apuzzi V; Riccone F; Saccà L; Oliviero U
Atherosclerosis; 2015 Dec; 243(2):407-13. PubMed ID: 26520894
[TBL] [Abstract][Full Text] [Related]
58. [Mesoglycan in acute and chronic venous insufficiency of the legs].
Sangrigoli V; Carrà G; Lazzara N; Micale F; Puleo MG; Bonaccorsi R
Clin Ter; 1989 May; 129(3):207-9. PubMed ID: 2527115
[TBL] [Abstract][Full Text] [Related]
59. [Behavior of endothelin plasma levels during iloprost infusion in patients with severe ischemia in the lower extremities].
Battistelli S; Borgogni T; Gori S; Manasse G
Minerva Cardioangiol; 1995 Jun; 43(6):257-62. PubMed ID: 7566538
[TBL] [Abstract][Full Text] [Related]
60. Effect of a single dose of mesoglycan on the human fibrinolytic system, and the profibrinolytic action of nine daily doses.
Vittoria A; Messa GL; Frigerio C; Celasco G; Auteri A
Int J Tissue React; 1988; 10(4):261-6. PubMed ID: 2977981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
